Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by folfirinox in metastatic pancreatic adenocarcinoma

Date

08 Oct 2016

Session

Poster Display

Presenters

Eric Assenat

Citation

Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371

Authors

E. Assenat1, C. de la Fouchardiere2, C. Mollevi3, E. Samalin1, F. Portales1, F. Desseigne2, C. Carenco1, M. Dupuy4, E. Lopez-Martinez5, C. Fiess6, T. Mazard1, M. Ychou1

Author affiliations

  • 1 Digestive Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 2 Digestive Oncology, Centre Léon Bérard, Lyon/FR
  • 3 Biometrics Unit, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 4 Medical Oncology, Hopital Saint-Eloi (Montpellier), Montpellier/FR
  • 5 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 6 Clinical Research, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
More

Resources

Background

Folfirinox (FFX) and Nab-paclitaxel/Gemcitabine (AG) showed significant improvement in efficacy compared to Gemcitabine alone in metastatic pancreatic cancer (mPC). Alternating AG and FFX may overcome resistance to primary therapy and delay tumor progression. We designed a multicenter phase I-II trial with a new sequential regimen of AG followed by FFX in first-line treatment of mPC. The phase I primary objective was to determine the recommended AG and FFX doses. Primary endpoint was to determine the dose-limiting toxicities (DLTs). The phase II will assess the efficacy of the recommended doses.

Methods

AG and FFX were administered sequentially, each AG cycle followed by a FFX cycle. Dose-escalation was:

One cycle D1 = D57 AG (mg/m2) D1, D8, D15 FFX (mg/m2) D29, D43
Dose level Nab-paclitaxel Gemcitabine Oxaliplatin Irinotecan LV 5-FU
1 100 800 70 150
2a 100 800 85 180 Leucovorin: 200
2b 125 1000 70 150 5-FU bolus: 400
3 125 1000 85 180 5-FU infusion: 2400

Chemotherapeutic agents were administered according to standard practice, except for Gemcitabine (10mg/m2/min).

Results

From September 2013 to October 2015, 33 mPC patients were included: 7, 6 and 7 patients in levels 1, 2a and 2b, respectively, and 13 in level 3. 31 patients were evaluable for tolerance (2 not evaluable at levels 1 and 2b). Patients' characteristics at baseline were: male 54.8%, median age 61 years (42-75), ECOG PS 0 (35.5%) or 1 (64.5%). Five DLTs were reported: 1, 2 and 2 in levels 2a, 2b and 3, respectively. All DLTs were grade 4 transient, asymptomatic neutropenia with spontaneous resolution. They occurred at treatment initiation, probably due to the absence of prophylactic GCSF treatment during AG administration. There was no limiting neurotoxicity. Promising efficacy results (response and survival) will be presented at the meeting.

Conclusions

This new regimen alternating AG and FFX shows acceptable toxicity and promising efficacy results. The recommended dose (level 3) is being confirmed in a 12 patient-expansion cohort before starting the phase II accrual.

Clinical trial identification

NCT01964287

Legal entity responsible for the study

Institut régional du Cancer de Montpellier (ICM), France

Funding

This project was supported by Celgene.

Disclosure

E. Assenat: Honoraria: Ipsen, Novartis, Sanofi Consulting. Advisory Role: Ipsen. Research Funding: Bayer (Institution), Celgene (Institution). Travel, Accomodations, Expenses: Novartis, Celgene.

C. de la Fouchardiere: Consulting or Advisory Role: Bayer, Celgene Research. Funding: Roche/Genentech (Institution). Travel, Accomodations, Expenses: Ipsen, Bayer, Roche. E. Samalin: Honoraria: Lilly, Sanofi, Amgen, Roche. Consulting or Advisory Role: Amgen, Sanofi, Roche. Research funding: Bayer (institution). Travel, Accommodations, Expenses: Novartis, Lilly, Ipsen, Roche. F. Portales: Honoraria: Sanofi Consulting or Advisory Role: Sanofi. Research funding: Celgene (Institution). Travel, Accommodations, Expenses: Ipsen. T. Mazard: Honoraria: Amgen, Sanofi. Research funding: Roche, Parma AG (Institution). Travel, Accomodations, Expenses: Amgen. M. Ychou: Honoraria: Bayer, Merck-Serono, Roche/Genentech, Celgene. Consulting or Advisory Role: Bayer, Celgene, Roche. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings